Nabeel Khan1, Dhruvan Patel, Dawei Xie, Tyler Pernes, James Lewis, Yu-Xiao Yang. 1. 1Department of Gastroenterology, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA; 2Division of Gastroenterology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA; 3Center of Clinical Epidemiology and Biostatistics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA; 4Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Abstract
INTRODUCTION: The clinic course of SARS-CoV-2 among patients with inflammatory bowel disease (IBD) has been extensively studied. However, there is a paucity of data on whether patients with IBD have an increased risk of developing SARS-CoV-2 with compared with patients without IBD. METHODS: We conducted a nationwide retrospective cohort study in the US Veterans' Affairs healthcare system from January 1, 2020, to June 30, 2020. We matched each patient with IBD with 2 patients without IBD on age, sex, race, location, and comorbidities. The outcome of interest was development of SARS-CoV-2. RESULTS: Among 38,378 patients with IBD and 67,433 patients without IBD, 87 (0.23%) and 132 (0.20%) patients developed incident SARS-CoV-2 infection, respectively (P = 0.29). DISCUSSION: Patients with IBD are not at a significantly increased risk of developing SARS-CoV-2 infection when compared with patients without IBD.
INTRODUCTION: The clinic course of SARS-CoV-2 among patients with inflammatory bowel disease (IBD) has been extensively studied. However, there is a paucity of data on whether patients with IBD have an increased risk of developing SARS-CoV-2 with compared with patients without IBD. METHODS: We conducted a nationwide retrospective cohort study in the US Veterans' Affairs healthcare system from January 1, 2020, to June 30, 2020. We matched each patient with IBD with 2 patients without IBD on age, sex, race, location, and comorbidities. The outcome of interest was development of SARS-CoV-2. RESULTS: Among 38,378 patients with IBD and 67,433 patients without IBD, 87 (0.23%) and 132 (0.20%) patients developed incident SARS-CoV-2 infection, respectively (P = 0.29). DISCUSSION: Patients with IBD are not at a significantly increased risk of developing SARS-CoV-2 infection when compared with patients without IBD.
Authors: Fernando Magro; Alexandre Nuzzo; Cândida Abreu; Diogo Libânio; Iago Rodriguez-Lago; Katarzyna Pawlak; Marcus Hollenbach; Willem P Brouwer; Keith Siau Journal: United European Gastroenterol J Date: 2021-06-30 Impact factor: 6.866
Authors: Howard S Herman; Max P Rosenthaler; Noon Elhassan; Janice M Weinberg; Venkata R Satyam; Sharmeel K Wasan Journal: Dig Dis Sci Date: 2022-02-17 Impact factor: 3.487
Authors: Anna Viola; Marco Muscianisi; Raffaele Li Voti; Giuseppe Costantino; Angela Alibrandi; Walter Fries Journal: Eur J Gastroenterol Hepatol Date: 2021-12-01 Impact factor: 2.586